PMP22 and chronic inflammatory demyelinating polyradiculoneuropathy: Considering the long-term side effects of the corticosteroids and immunosuppressants currently used to suppress relapse in NF155+ CIDP patients, more efficacious and safer drugs for NF155+ CIDP treatment need to be developed.